

Economic Burden Associated with Pre-existing Substance Abuse in Patients with Negative Symptoms Schizophrenia: US Administrative Claims Data Analysis

The Authority in RWE

Mosadoluwa Afolabi, Gideon Aweh, Ishveen Chopra, Keshia Muaghn STATinMED LLC, Dallas, Texas, USA

INTRODUCTION

- Schizophrenia is a chronic and debilitating mental illness characterized by a diminished capacity for learning, working, self-care, and interpersonal relationships.⁽¹⁻³⁾ It Is also responsible for nearly \$343.2 billion in excess economic burden in the US, as of 2019.⁽⁴⁾
- It presents with positive and negative symptoms as well as cognitive deficits which is worsened by co-existing substance abuse disorders.
- Substance use disorders (SUD) is highly prevalent in schizophrenia, with approximately 47% of patients with schizophrenia suffering from SUD in epidemiological and clinically based samples.⁽⁵⁾ Additionally, it was found that patients who presented to ER with substance abuse were about 3 times more likely to develop schizophrenia, regardless of the presence of psychosis, when compared to the general population.⁽⁶⁾
- Despite antipsychotic effectiveness against positive symptoms, there remains a treatment gap in managing negative symptoms schizophrenia (NSS). The lack of population-based studies focused on NSS in the United States has resulted in limited knowledge of the population affected by these symptoms

OBJECTIVES

- Examine how initial substance abuse influences the economic burden and resource us among patients with negative symptoms schizophrenia.
- The findings from this study will add to the body of scientific knowledge of the impact of NSS in the face of an apparent limited efficacy of antipsychotics in treatment of NSS.

METHODS

STUDY DESIGN

 It is a retrospective longitudinal observational study that utilized de-identified administrative claims from STATinMED RWD Insights data (01/01/2016-09/30/2022).

STUDY POPULATION:

- · Included were patients with schizophrenia (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] code: F20.XX and NSS (ICD-10-CM: F20.5; index date=first NSS diagnosis date) during the identification period 01/01/2017-09/30/2021, aged ≥13 years at index, 12-month continuous capture pre- (baseline) and post- (follow-up) index date, and evidence of baseline antipsychotic use.
- All patients with NSS in the baseline period were excluded. Patients were categorized based on the presence (cases) or absence (controls) of baseline substance abuse (alcohol/ drug abuse diagnosis).

STUDY OUTCOMES:


· Statistical Outcomes examined for the follow-up period included all-cause, mental health (MH)-, and schizophrenia-related health care resource utilization (HCRU) and costs per patient per year.

STATISTICAL ANALYSIS: Patient demographics, clinical characteristics,

and other psychiatric and neurodevelopmental comorbidities were assessed for the baseline period.

 Cohorts were matched using inverse probability treatment weighting (IPTW) and Generalized Linear Models (GLMs) were performed.





aseline Period Follow-up Period (12 months pre-index) (12 months post-index




FIGURE 1: Patient Selection Criteria

≥1 diagnosis of NSS during identification period (ICD- 10-CM: F20.5) (01JAN2017 - 305EP2021) (index date first claim for NSS) N=16,439	
>13 years of ago on index data	

Continuous capture with either medical or pharmacy benefits for 12 months pre index date (baseline period index date - 365 to index date -1); all patients were

required to have had a 12-month baseline period N=14.215



Of the 5,691 NSS patients, 24.6% were cases.

RESULTS

- Cases were significantly younger (mean age: 44 vs 52), had higher proportion of patients insured by Medicaid (87% vs 62%), higher comorbidities including Quan-Charlson comorbidity index score (mean: 1.7 vs 1.3), depression (53% vs 22%), uncomplicated hypertension (48% vs 38%), mild liver disease (14% vs 5%), psychoses (96% vs 75%), anxiety (45% vs 21%), bipolar disorder (43% vs 17%), suicidal ideation/attempt/intentional self-harm (44% vs 8%), and trauma- and stressor-related disorders (21% vs 7%).
- Following IPTW (Table 3), cases had a significantly greater mean number inpatient admissions (8.7 vs 6.3). outpatient ER visits (5.7 vs 2.8), lower prescription counts (41.92 vs 55.04), and higher mean outpatient ER costs (\$2,276 vs \$1,439).
- GLM analysis also showed cases had higher mean number of inpatient admissions (10.5 vs 5.7), outpatient visits (22.7 vs 16.5), lower prescription counts (40.1 vs 55.6), and higher outpatient visit costs (\$12,505 vs \$8,722).
- · These findings were generally consistent with MH- and schizophrenia-related HCRU and costs; however, MH-related total costs were significantly higher (\$32,195 vs \$25.003; all p<0.05).

TABLE 3: HCRU for All-Cause and Schizophrenia-Related after IPTW Adjustment

	Baseline Subtance Abuse	No Baseline Subtance Abuse	p-value
Mean/N / SD/%	(n=1,400)	(n=4,291)	
se HCRU			
≥1 inpatient stay	69%	51%	<.0001
≥1 outpatient visit	98%	98%	0.1848
≥1 pharmacy visit	79%	82%	0.0077
Inpatient LOS	10.56	14.04	0.6987
Number of inpatient admissions	16.84	14.90	<.0001
Number of outpatient visits	28.53	23.62	0.0005
Number of pharmacy visits	22.13	22.19	<.0001
Number of prescription visits	48.55	55.65	<.0001
ohrenia HCRU			
≥1 inpatient stay	51%	40%	<.0001
≥1 outpatient visit	87%	89%	0.0116
≥1 pharmacy visit	68%	75%	<.0001
Inpatient LOS	13.16	13.09	0.1895
Number of inpatient admissions	8.43	8.58	0.0073
Number of outpatient visits	21.09	16.89	0.6941
Number of pharmacy visits	6.99	7.46	<.0001
Number of prescription visits	9.58	10.57	<.0001

TABLE 1: Baseline Demographic Characteristics for the Study Cohorts

	BL Substance Abuse		No BL Substance Abuse		Pre- IPTW	BL Substance Abuse		No BL Substance Abuse		Post- IPTW
Mean/N / SD/%	(n=1	,400)	(n=4,291)		STD	(n=1	,400)	(n=4,291)		STD
mographics										
e	43.79	13.34	51.99	15.41	56.92	49.18	14.33	49.72	15.75	3.62
le	1,008	72%	2,447	57%	31.68	825.13	59%	2586.70	60%	2.74
male	392	28%	1,844	43%	31.68	574.87	41%	1704.30	40%	2.74
yer Channel										
mmercial	89	6%	479	11%	17.06	151.59	11%	431.33	10%	2.54
dicare	91	7%	1,102	26%	54.07	267.67	19%	897.00	21%	4.46
dicaid	1,217	87%	2,679	62%	58.70	978.21	70%	2937.58	68%	3.06
ners ^a	3	0%	31	1%	7.45	2.53	0%	25.09	1%	6.55

TABLE 2: Baseline Clinical Characteristics for the Study Cohorts

	BL Substance Abuse (n=1,400)		No BL Substance Abuse (n=4,291)		Pre- IPTW	BL Substance Abuse (n=1,400)		No BL Substance Abuse (n=4,291)		Post- IPTW STD	
Mean/N / SD/%					STD						
Clinical Characteristics and Comorbidity											
ссі	1.73	2.89	1.32	2.54	15.05	1.49	2.68	1.40	2.60	3.28	
Depression	742	53%	962	22%	66.48	491.81	35%	1292.81	30%	10.68	
Hypertension, uncomplicated	678	48%	1,651	38%	20.18	122.69	9%	301.72	7%	6.42	
Liver disease, mild	189	14%	195	5%	31.64	113.03	8%	279.37	7%	6.01	
Psychoses	1,339	96%	3,197	75%	62.10	1134.91	81%	3422.77	80%	3.27	
Mental Health											
Anxiety and fear-related disorders	632	45%	885	21%	54.05	418.10	30%	1155.09	27%	6.53	
Bipolar and related disorders	608	43%	736	17%	59.66	351.07	25%	1016.84	24%	3.21	
Suicidal ideation/attempt/intentional self-harm	613	44%	357	8%	88.31	247.76	18%	735.25	17%	1.48	
Trauma- and stressor-related disorders	291	21%	284	7%	42.09	179.19	13%	445.35	10%	7.57	

STRENGTHS & LIMITATIONS

- The usage of claims data comes with some restrictions. A diagnosis code on a medical claim may be improperly coded or used as a rule-out criteria rather than the actual condition, therefore its existence does not necessarily indicate the occurrence of a disease.
- Additionally, the existence of a claim for a filled prescription does not prove that the medication was taken as directed or that it was consumed.

CONCLUSION

- Substance abuse and schizophrenia are strongly correlated with a high prevalence of SUD found in patients with schizophrenia. Substance abuse is associated with a higher risk of developing schizophrenia, as well as worsening existing symptoms of schizophrenia and NSS.
- · Our study finds that baseline substance abuse further increases the economic burden associated with NSS

ABBREVIATIONS

Abbreviations: AP, antipsychotic, BL, Baseline, CCI, Quan Charlson Comorbidity Index Score, CI, confidence interval, HCRU, healthcare resource utilization, ICD, International Classification of Diseases, IPTW, Inverse probability of treatment weighting, LOS, length of stay, NSS, Negative Symptom Schizophrenia, PPPY, Per Person Per Year SD, standard deviation, STD, standardized difference

REFERENCES

All-cause HCRU

Number of Utilizatio

All-cause Cost PPPY (2022 \$US) Inpatient stay costs Outpatient visit cos Pharmacy costs Total costs

Schizophrenia HCRU

Number of Utilizatio


Inpatient LOS Number of inpatient a Number of outpatient

- 3 841705
- 3. Association AP. American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006. American Psychiatric Pub; 2006.
- Psychiatry. 2022;83(6):22m14458. 5. Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234-258.
- 6. Myran DT, Harrison LD, Pugliese M, et al. Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis. JAMA Psychiatry. 2023;80(11):1169-1174.



N=16,383

FIGURE 2: Costs (PPPY) for All-Cause and Schizophrenia-Related after IPTW Adjustment







FIGURE 2A: HCRU and Costs for All-Cause and Schizophrenia-Related GLM model adjusted for patients' demographics and comorbidities



1. Lafeuille MH, Gravel J, Lefebyre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. Nov 2013;16(11):1290-9. doi:10.3111/13696998.201

- 2. Saha S. Chant D. Welham J. McGrath J. A systematic review of the prevalence of schizophrenia. PLoS medicine, 2005:2(5):e141
- 4. Kadakia A, Catillon M, Fan Q, et al. The economic burden of schizophrenia in the United States. J Clin